inclusion criteria: - hospitalized with coronavirus (sars-cov-2) infection, confirmed by polymerase chain reaction (pcr) test or other commercial or public health assay in any specimen, as documented by either of the following: - pcr positive in sample collected <72 hours prior to randomization; or - pcr positive in sample collected ≥72 hours prior to randomization (but no more than 14 days prior to randomization), documented inability to obtain a repeat sample (for example, due to lack of testing supplies, limited testing capacity, results taking >24 hours, etc.) and progressive disease suggestive of ongoing sars-cov-2 infection. - requires supplemental oxygen at the time of study entry and at randomization. - have indicators of risk of progression: at least 1 inflammatory markers >upper limit of normal (uln) (c reactive protein [crp], d dimer, lactate dehydrogenase [ldh], ferritin) with at least 1 instance of elevation >uln within 2 days before study entry.

inclusion criteria: - hospitalized with coronavirus (sars-cov-2) infection, confirmed by polymerase chain reaction (pcr) test or other commercial or public health assay in any specimen, as documented by either of the following: - pcr positive in sample collected <72 hours prior to randomization; or - pcr positive in sample collected ≥72 hours prior to randomization (but no more than 14 days prior to randomization), documented inability to obtain a repeat sample (for example, due to lack of testing supplies, limited testing capacity, results taking >24 hours, etc.) and progressive disease suggestive of ongoing sars-cov-2 infection. - requires supplemental oxygen at the time of study entry and at randomization. - have indicators of risk of progression: at least 1 inflammatory markers >upper limit of normal (uln) (c reactive protein [crp], d dimer, lactate dehydrogenase [ldh], ferritin) with at least 1 instance of elevation >uln within 2 days before study entry.

inclusion criteria: - hospitalized with coronavirus (sars-cov-2) infection, confirmed by polymerase chain reaction (pcr) test or other commercial or public health assay in any specimen, as documented by either of the following: - pcr positive in sample collected <72 hours prior to randomization; or - pcr positive in sample collected ≥72 hours prior to randomization (but no more than 14 days prior to randomization), documented inability to obtain a repeat sample (for example, due to lack of testing supplies, limited testing capacity, results taking >24 hours, etc.) and progressive disease suggestive of ongoing sars-cov-2 infection. - have evidence of pneumonia (spo2 <94 or pao2/fio2 [or spo2/fio2] ratio <300 mmhg or chest imaging findings consistent with pneumonia), or have evidence of active covid infection (with clinical symptoms including any of the following: fever, vomiting, diarrhea, dry cough, tachypnea defined as respiratory rate >24 breaths/minute). - have indicators of risk of progression: at least 1 inflammatory markers >upper limit of normal (uln) (c reactive protein [crp], d dimer, lactate dehydrogenase [ldh], ferritin) with at least 1 instance of elevation >uln within 2 days before study entry.

inclusion criteria: - hospitalized with coronavirus (sars-cov-2) infection, confirmed by polymerase chain reaction (pcr) test or other commercial or public health assay in any specimen, as documented by either of the following: - pcr positive in sample collected <72 hours prior to randomization; or - pcr positive in sample collected ≥72 hours prior to randomization (but no more than 14 days prior to randomization), documented inability to obtain a repeat sample (for example, due to lack of testing supplies, limited testing capacity, results taking >24 hours, etc.) and progressive disease suggestive of ongoing sars-cov-2 infection. - have evidence of pneumonia (spo2 <94 or pao2/fio2 [or spo2/fio2] ratio <300 mmhg or chest imaging findings consistent with pneumonia), or have evidence of active covid infection (with clinical symptoms including any of the following: fever, vomiting, diarrhea, dry cough, tachypnea defined as respiratory rate >24 breaths/minute). - have indicators of risk of progression: at least 1 inflammatory markers >upper limit of normal (uln) (c reactive protein [crp], d dimer, lactate dehydrogenase [ldh], ferritin) with at least 1 instance of elevation >uln within 2 days before study entry.